BioMarin Pharmaceutical (BMRN)
(Delayed Data from NSDQ)
$91.20 USD
-0.86 (-0.93%)
Updated Apr 24, 2024 04:00 PM ET
After-Market: $91.23 +0.03 (0.03%) 7:58 PM ET
3-Hold of 5 3
D Value D Growth D Momentum D VGM
Fundamental Charts
About Cash from Investing (Quarterly)
The company's quarterly Cash from Investing value is the sum of the company's current quarter cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
BMRN 91.20 -0.86(-0.93%)
Will BMRN be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for BMRN based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for BMRN
BioMarin (BMRN) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates
BioMarin Pharmaceutical (BMRN) Tops Q1 Earnings Estimates
BMRN: What are Zacks experts saying now?
Zacks Private Portfolio Services
Is a Surprise Coming for BioMarin (BMRN) This Earnings Season?
AstraZeneca (AZN) to Report Q1 Earnings: Here's What to Expect
Gear Up for BioMarin (BMRN) Q1 Earnings: Wall Street Estimates for Key Metrics
Other News for BMRN
Biomarin Pharmaceutical Inc (BMRN) Q1 2024 Earnings Call Transcript Highlights: Strong Growth ...
BioMarin: Q1 Earnings Snapshot
BioMarin Reports Record Financial Results for the First Quarter 2024
BMRN Stock Earnings: Biomarin Pharmaceutical Beats EPS, Misses Revenue for Q1 2024
BioMarin Pharmaceutical, Inc. (BMRN) Q1 2024 Earnings Call Transcript